Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet

References

• Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 2000;16:5-15
   PubMed Web of Science ®Google Scholar
• Dan M. The use of fluoroquinolones in gonorrhoea: the increasing problem of resistance. Expert Opin Pharmacother 2004;5:829-54
   PubMed Web of Science ®Google Scholar
• Albertson TE, Morrissey BM, Chan AL. Are fluoroquinolones superior antibiotics for the treatment of community-acquired pneumonia? Curr Infect Dis Rep 2012;14:317-29
   PubMed Web of Science ®Google Scholar
• Garcia-Garrote F, Cercenado E, Martin-Pedroviejo J, et al. Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens. J Antimicrob Chemother 2001;47:681-4
   PubMed Web of Science ®Google Scholar
• Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999;341:233-9
   PubMed Web of Science ®Google Scholar
• Ho PL, Que TL, Tsang DN, et al. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999;43:1310-13
   PubMed Web of Science ®Google Scholar
• Tapsall J. Multidrug-resistant Neisseria gonorrhoeae. Can Med Assoc J 2009;180:268-9
   PubMed Web of Science ®Google Scholar
• Kwon AR, Min YH, Ryu JM, et al. In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent. J Antimicrob Chemother 2006;58:684-8
   PubMed Web of Science ®Google Scholar
• Park HS, Jung SJ, Kwak JH, et al. DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae. Int J Antimicrob Agents 2010;36:97-8
   PubMed Web of Science ®Google Scholar
• Jones RN, Biedenbach DJ, Ambrose PG, et al. Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains. Diagn Microbiol Infect Dis 2008;62:110-12
   PubMed Web of Science ®Google Scholar
• Kim HJ, Seol MJ, Park HS, et al. Antimicrobial activity of DW-224a, a new fluoroquinolone, against Streptococcus pneumoniae. J Antimicrob Chemother 2006;57:1256-8
   PubMed Web of Science ®Google Scholar
• Kosowska-Shick K, Credito K, Pankuch GA, et al. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. Antimicrob Agents Chemother 2006;50:2064-71
   PubMed Web of Science ®Google Scholar
• Park HS, Kim HJ, Seol MJ, et al. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob Agents Chemother 2006;50:2261-4
   PubMed Web of Science ®Google Scholar
• Han J, Kim JC, Chung MK, et al. Subacute toxicity and toxicokinetics of a new antibiotic, DW-224a, after single and 4-week repeated oral administration in dogs. Biol Pharmaceut Bull 2003;26:832-9
   PubMed Web of Science ®Google Scholar
• Kim EJ, Shin WH, Kim KS, et al. Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent. Drug Chem Toxicol 2004;27:295-307
   PubMed Web of Science ®Google Scholar
• World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects, 59th WMA General Assembly, Seoul, October 2008. Available at: http://www.wma.net/en/30publications/10policies/b3/17c.pdf [Last accessed 22 June 2011]
   Google Scholar
• Guideline for Good Clinical Practice E6 (R1). Step 4 version, ICH Harmonised Tripartite Guideline, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf [Last accessed 22 June 2011]
   Google Scholar
• Jung TR, Hwang SW, Lee JU, et al. Comparative consistency between obesity determination standards using body mass index and ideal body weight. J Korean Acad Fam Med 2001;22:1765-71
   Google Scholar
• Jin HE, Lee KR, Kang IH, et al. Determination of zabofloxacin in rat plasma by liquid chromatography with mass spectrometry and its application to pharmacokinetic study. J Pharmaceut Biomed Anal 2011;54:873-7
   PubMed Web of Science ®Google Scholar
• Jin HE, Kang IH, Shim CK. Fluorescence detection of Zabofloxacin, a novel fluoroquinolone antibiotic, in plasma, bile, and urine by HPLC: the first oral and intravenous applications in a pharmacokinetic study in rats. J Pharm Pharmaceut Sci 2011;14:291-305
   PubMed Web of Science ®Google Scholar
• Sauter R, Steinijans VW, Diletti E, et al. Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1992;30(Suppl 1):S7-30
   PubMedGoogle Scholar
• Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharmaceut 1987;15:657-80
   PubMedGoogle Scholar
• Korea Food and Drug Administration. Bioequivalence guideline in Korea [in Korean]. Available at: http://www.kfda.go.kr/index.kfda?mid226&pageNo1&seq139&cmdv [Last accessed 9 December 2011]
   Google Scholar
• Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 2001;40:169-87
   PubMed Web of Science ®Google Scholar
• Ball P, Mandell L, Niki Y, et al. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 1999;21:407-21
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Walkty A, Vercaigne L, et al. The new fluoroquinolones: a critical review. Can J Infect Dis 1999;10:207-38
   PubMedGoogle Scholar
• Mandell LA, Ball P, Tillotson G. Antimicrobial safety and tolerability: differences and dilemmas. Clin Infect Dis 2001;32(Suppl 1):S72-9
   PubMedGoogle Scholar
• Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology 2011;120:103-10
   PubMed Web of Science ®Google Scholar